Drug Type Small molecule drug |
Synonyms |
Mechanism CysLT1 antagonists(Cysteinyl leukotriene receptor 1 antagonists), NKCC1 inhibitors(Solute carrier family 12 member 2 inhibitors), NKCC2 inhibitors(Sodium-(potassium)-chloride cotransporter 2 inhibitors) + [5] |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization Stalicla SAStartup |
Active Organization- |
Inactive Organization Stalicla SAStartup |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC17H20N2O5S |
InChIKeyMAEIEVLCKWDQJH-UHFFFAOYSA-N |
CAS Registry28395-03-1 |
Start Date07 Dec 2020 |
Sponsor / Collaborator Stalicla SAStartup |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Autism Spectrum Disorder | Phase 1 | US | Stalicla SAStartup | 07 Dec 2020 |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
Phase 1 | 12 | (STP1 Low Dose) | kuycruzdrm(gfduregygy) = pnwuoxetyh dnlieewskf (ghfsdjpvkb, becvvefwwd - zddnrvdzfv) View more | - | 08 Nov 2024 | ||
(STP1 High Dose) | kuycruzdrm(gfduregygy) = izbjqqmbew dnlieewskf (ghfsdjpvkb, jhtymhewms - wbpnsaolyq) View more |